ClinicalTrials.gg
Active, not recruitingNCT06822491PRODARTUpdated Nov 18, 2026

Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response

An observational study in Prostate Carcinoma, Localized Prostate Adenocarcinoma and Stereotactic Body Radiotherapy, sponsored by University of Zurich. Active, not recruiting at 1 site in Switzerland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Zurich · Observational

How we know

Updated Nov 18, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.

Planned enrollment
25th of 28
28 · median 219
Started
2024
with 9 others
Observational
28 of 136
9 open now
Primary completion
2026-10
later than 16 of 57 live
Registered
115th of 136
by date
Lead sponsor
8 of 136
University of Zurich

Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 25th largest by planned enrollment of the 28 observational ones that give a count, is one of 10 that started in 2024, is one of 28 observational ones, reaches primary completion later than 16 of the 57 other live ones, and was the 115th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Prostatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of this phase II study is to determine the early multiparametric magnetic resonance imaging response of the dominant intraprostatic lesion and correlate these findings with prostate specific antigen response in patients with intermediate to (very) high risk localized prostate cancer treated with online adaptive stereotactic radiotherapy without intraprostatic fiducial markers.

Read the detailed description

Background: Stereotactic body radiotherapy (SBRT) is an established standard of care treatment for localized prostate cancer. Recent pathological studies suggest the presence of a dominant intraprostatic lesion (DIL) within the prostate, which serve as a central driver of tumor aggressiveness and recurrence after treatment. Prostate-specific antigen (PSA) monitoring is the cornerstone of follow-up, though time to PSA nadir after SBRT can extend to 3 years.

Methods: This phase II observational study aims to evaluate the correlation between PSA response and early multiparametric magnetic resonance imaging (mpMRI) changes of the DIL(s) at 6- or 9-months following online adaptive SBRT for intermediate to (very) high risk localized prostate cancer. The primary outcome is the achievement of local control as assessed by mpMRI at 6 months post-SBRT or, if necessary, at 9 months post-SBRT (in case of image non complete response at 6 months). A complete imaging response is defined as the disappearance of all morphological and functional mpMRI changes of PIRADS (Prostate Imaging Reporting and Data System) ≥3 lesion(s) correlating with Gleason ≥7a pathology. No confirmatory biopsies will be conducted. The required sample size for this study will be 28 patients, assuming a complete response rate of 80% at 6 months, targeting an acceptable margin of error with 95% confidence, and a margin of error of 15%.

03

Conditions studied

  • Prostate Carcinoma
  • Localized Prostate Adenocarcinoma
  • Stereotactic Body Radiotherapy
  • Stereotactic Radiotherapy
  • Magnetic Resonance Imaging
  • Multiparametric MRI

Browse trials for

Keywords

  • DIL
  • Dominant intraprostatic lesion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred to our tertiary referral centre for prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed localized prostate cancer who are planned for CT- or MRI-adaptive SBRT for prostate cancer;
  • Presence of PIRADS ≥3 lesion(s) in a mpMRI correlating with Gleason ≥7 score at diagnosis;
  • Intermediate to (very) high risk localized prostate cancer (≤ cT3b and cN0);
  • performance status of 0-2;
  • Age ≥ 18 years;
  • PSMA PET ≤3 months is compulsory for high-risk prostate cancer (as part of clinical routine);
  • Written .
  • Willingness and ability to comply with schedule

Exclusion criteria

Exclusion Criteria:

  • Previous (≤10 years) local therapy of the prostate including transurethral resection of the prostate (TURP),
  • for MRI;
  • Previous (≤10 years) radiotherapy in the pelvis;
  • Lymph node or distant metastases (i.e. no localized prostate cancer);
  • Participation in a clinical trial which might influence the results of this project;
  • Claustrophobic anxiety;
  • Uncontrolled intercurrent illness;
  • Relation to investigator (family or professional)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Multiparametric magnetic resonance imaging local control of the dominant intraprostatic lesion

    To study multiparametric magnetic resonance imaging (mpMRI) local control of Prostate Imaging Reporting and Data System (PIRADS) ≥3 lesion(s) after SBRT. An image complete response is defined as disappearance of all morphological and functional PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology in mpMRI.

    Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

  2. Correlation of early prostate-specific antigen response with early multiparametric magnetic resonance imaging changes

    To correlate early prostate-specific antigen response with early multiparametric magnetic resonance imaging changes of the PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology

    Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

Secondary outcomes

  1. Correlation of late prostate-specific antigen response with early multiparametric magnetic resonance imaging changes

    To correlate late prostate-specific antigen response with early multiparametric magnetic resonance imaging changes of the PIRADS ≥3 lesion(s) correlating with Gleason ≥7a pathology

    Time frame: Yearly (up to 5 years post SBRT)

  2. Correlation of genitourinary and gastrointestinal toxicity with early multiparametric magnetic resonance imaging changes

    Correlating genitourinary and/or gastrointestinal toxicity (according to common terminology criteria for adverse events \[CTCAE\] version 5.0) with structural and/or functional changes of the prostate and/or surrounding organs on early multiparametric magnetic resonance imaging

    Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

  3. Correlation of prostate quality of life with early multiparametric magnetic resonance imaging changes

    Quality of life (according to EPIC-26) and relation to early structural and/or functional changes of the prostate and/or surrounding organs on multiparametric magnetic resonance imaging

    Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

  4. To evaluate prostate volume change during and after adaptive prostate SBRT and to correlate to treatment toxicity.

    To evaluate prostate volume change intra-treatment and after adaptive prostate SBRT and to correlate to treatment toxicity.

    Time frame: Intra-treatment (within 1 week before the last fraction of SBRT) and 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

  5. Exploratory image analysis

    Quantitative imaging features will be used to predict outcome and side effects on the different images.

    Time frame: 6 months after SBRT. In cases with image non-complete response at 6 months, 3 months later (in total 9 months after SBRT) an additional mpMRI will be performed.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this trial after de-identification. Other documents may be shared include the study protocol.

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months after article publication.

Access criteria: Proposals to access study data should send request to matthias.guckenberger@usz.ch. To gain access, data requesters must sign data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2026, 26 months.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's 26 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 12, 2025
StartActual
Aug 20, 2024
Primary completionActual
Oct 30, 2026was Jun 2026
CompletionEst.
Jun 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Oct 30, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Jun 2026→Oct 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06822491
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Aug 20, 2024
Primary completion
Oct 30, 2026
Completion
Jun 2031 (estimated)
Last update
Nov 18, 2026

Study contacts

Matthias Guckenberger, Prof. Dr. med.
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion